论文部分内容阅读
目的:评价雷珠单抗玻璃体内注射治疗孤立息肉的2型息肉样脉络膜血管病变(PCV)的临床效果。方法:回顾性分析郑州市第二人民医院2016年12月至2019年6月孤立息肉的2型PCV 33例(33只眼)的临床资料。采用雷珠单抗玻璃体内注射治疗，每月1次，共6次。观察治疗后3、6及12个月的视力、中央视网膜厚度(CRT)、视网膜色素上皮层(RPE)脱离和息肉的变化。随访12个月。结果:治疗后不同时间点视力均有提高(n F＝21.502，n P<0.05)，CRT均有减少(n F＝296.290，n P<0.05)。术后11例(33.3%)RPE脱离逐渐降低。息肉消退率为100%(33/33)。n 结论:雷珠单抗玻璃体内注射治疗孤立息肉的2型PCV视力明显提高，CRT明显降低，息肉消退率高。“,”Objective:To evaluate the clinical efficacy of intravitreal injection of ranibizumab (IVR) for the treatment of type 2 polypoidal choroidal vasculopathy (PCV) with isolated polyp.Methods:The clinical data of 33 eyes of 33 cases with type 2 PCV from Dec. 2016 to Jun. 2019 in Zhengzhou Municipal Second People’s Hospital were analyzed retrospectively. All patients received 6 times of IVR treatment once a month. The visual acuity, central retinal thickness (CRT), pigment epithelial detachment (PED) and polyp change were observed at 3, 6, and 12 months after treatment. The follow-up time was 12 months.Results:The visual acuity at different times after treatment all improved (n F=21.502, n P<0.05). CRT was all decreased after treatment (n F=296.290, n P<0.05). The PED gradually decreased in 11 patients (33.3%) postoperatively. The polyp regression rate was 100%(33/33).n Conclusion:The efficacy of IVR for the treatment of type 2 PCV is obvious, with the improvement of visual acuity, reduction of CRT and high rate of polyp regression.